A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Inclusion Criteria

• •1. Patients must have the ability to understand and voluntarily sign informed consent;
• •2. Age: over 18 years old;
• •3. Expected survival period ≥ 3 months;
• •4. Histologically or cytologically confirmed ES-SCLC (according to the Veterans Lung Administration Lung Study Group, VALG staging);
• •5. No prior systemic treatment for ES-SCLC;
• •6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1;
• •7. At least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Eval -uation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria;
• •8. Adequate hematologic and end organ function.
• •4. Are expected to require any other antineoplastic therapy while in study (PCI is allowed).
• •5. Have received administration of live attenuated vaccines within 4 weeks prior to the first administration of study drug or anticipation that such a live attenuated vaccine will be required during the study.